YOUR FRIENDS' ACTIVITY

    Medications/Drugs News Headlines

    • Valeant near deal to acquire Bausch & Lomb: source Greg Roumeliotis and Jessica Toonkel - Reuters - 16 mins ago

      By Greg Roumeliotis and Jessica Toonkel NEW YORK (Reuters) - Canada's Valeant Pharmaceuticals International is nearing a deal to acquire eye care company Bausch & Lomb … More »Valeant near deal to acquire Bausch & Lomb: source

      By Greg Roumeliotis and Jessica Toonkel NEW YORK (Reuters) - Canada's Valeant Pharmaceuticals International is nearing a deal to acquire eye care company Bausch & Lomb Holdings Inc from Warburg Pincus LLC for about $9 billion, a person familiar with the matter said on Friday. Valeant shares spiked to their highest level …

    • FDA warns of infections tied to Tennessee pharmacy MATTHEW PERRONE - AP - 24 mins ago

      WASHINGTON (AP) — Government health officials are investigating cases involving patients who suffered complications after being injected with potentially contaminated … More »FDA warns of infections tied to Tennessee pharmacy

      WASHINGTON (AP) — Government health officials are investigating cases involving patients who suffered complications after being injected with potentially contaminated medications made by a Tennessee specialty pharmacy.

    • New U.S. fears emerge over tainted compounded steroids Toni Clarke - Reuters - 6 mins ago

      By Toni Clarke (Reuters) - The Food and Drug Administration said on Friday it has received seven reports of illnesses in patients who took steroid injections compounded … More »New U.S. fears emerge over tainted compounded steroids

      By Toni Clarke (Reuters) - The Food and Drug Administration said on Friday it has received seven reports of illnesses in patients who took steroid injections compounded by a pharmacy in Tennessee. The FDA said full clinical information about the patients is still being gathered, but it suggested some of the problems were …

    • Novo obesity drug could launch in U.S. end 2014 Reuters - 9 hrs ago

      COPENHAGEN (Reuters) - Danish drug maker Novo Nordisk said it could launch obesity treatment liraglutide in the United States by the end of next year and rejected some … More »Novo obesity drug could launch in U.S. end 2014

      COPENHAGEN (Reuters) - Danish drug maker Novo Nordisk said it could launch obesity treatment liraglutide in the United States by the end of next year and rejected some analysts' doubts over the medicine's commercial potential. The world's biggest insulin producer is hoping the treatment for severe obesity will help to at …

    • Lawmaker would give FDA more oversight of drug compounding Toni Clarke - Reuters - 22 hrs ago

      By Toni Clarke WASHINGTON (Reuters) - Representative Edward Markey, a Democrat from Massachusetts, on Thursday became the latest lawmaker to propose legislation that … More »Lawmaker would give FDA more oversight of drug compounding

      By Toni Clarke WASHINGTON (Reuters) - Representative Edward Markey, a Democrat from Massachusetts, on Thursday became the latest lawmaker to propose legislation that would give the U.S. Food and Drug Administration greater regulatory authority over drug compounding. U.S. lawmakers, responding to a deadly meningitis outbreak …

    • New J&J anti-depressant related to 'Special K' party drug Ransdell Pierson - Reuters - 23 hrs ago

      By Ransdell Pierson NEW BRUNSWICK, New Jersey (Reuters) - Johnson & Johnson said it plans to seek approvals for 11 new drugs by 2017, including a treatment for patients … More »New J&J anti-depressant related to 'Special K' party drug

      By Ransdell Pierson NEW BRUNSWICK, New Jersey (Reuters) - Johnson & Johnson said it plans to seek approvals for 11 new drugs by 2017, including a treatment for patients with depression who have failed to benefit from standard medications. The intranasal drug, called esketamine, is closely related to a pediatric anesthetic …

    • BTG says interventional medicine buys could boost sales to $1 bln Paul Sandle - Reuters - Thu, May 23, 2013

      By Paul Sandle LONDON (Reuters) - British pharmaceutical company BTG announced two deals on Thursday that it said could create an interventional medicine business with … More »BTG says interventional medicine buys could boost sales to $1 bln

      By Paul Sandle LONDON (Reuters) - British pharmaceutical company BTG announced two deals on Thursday that it said could create an interventional medicine business with potential sales of $1 billion. Chief Executive Louise Makin told Reuters the deals would more than double BTG's revenues in the fast-growing market of targeting …

    • Nebraska attorney general wants abortion clinic nurse's license revoked Katie Schubert - Reuters - Wed, May 22, 2013

      By Katie Schubert OMAHA, Nebraska (Reuters) - Nebraska Attorney General Jon Bruning on Wednesday filed a petition to revoke the license of the only nurse at a controversial … More »Nebraska attorney general wants abortion clinic nurse's license revoked

      By Katie Schubert OMAHA, Nebraska (Reuters) - Nebraska Attorney General Jon Bruning on Wednesday filed a petition to revoke the license of the only nurse at a controversial abortion clinic in the state for allegedly providing substandard care and improperly administering drugs. ...

    • AP10ThingsToSee - In this picture provided by the Cancer Center and Institute of Oncology in Gliwice, Poland, a 33-year-old Polish man whose face was torn off by stone-cutting machinery is shown after undergoing a face transplant. Doctors performed the surgery on May 15 in a 27-hour operation. (AP Photo/Cancer Center and Institute of Oncology in Gliwice)
      Polish man gets quick face transplant after injury MONIKA SCISLOWSKA - AP - Wed, May 22, 2013

      WARSAW, Poland (AP) — A 33-year-old Polish man received a face transplant just three weeks after being disfigured in a workplace accident, in what his doctors said Wednesday … More »Polish man gets quick face transplant after injury

      AP10ThingsToSee - In this picture provided by the Cancer Center and Institute of Oncology in Gliwice, Poland, a 33-year-old Polish man whose face was torn off by stone-cutting machinery is shown after undergoing a face transplant. Doctors performed the surgery on May 15 in a 27-hour operation. (AP Photo/Cancer Center and Institute of Oncology in Gliwice)

      WARSAW, Poland (AP) — A 33-year-old Polish man received a face transplant just three weeks after being disfigured in a workplace accident, in what his doctors said Wednesday is the fastest time frame to date for such an operation. It was Poland's first face transplant.

    • A view of the Merck & Co. campus in Linden, New Jersey
      Merck's insomnia drug moves a step closer to U.S. approval Toni Clarke - Reuters - Wed, May 22, 2013

      By Toni Clarke WASHINGTON (Reuters) - Merck & Co's experimental insomnia drug moved a step closer to U.S. approval on Wednesday after a panel of medical experts said … More »Merck's insomnia drug moves a step closer to U.S. approval

      A view of the Merck & Co. campus in Linden, New Jersey

      By Toni Clarke WASHINGTON (Reuters) - Merck & Co's experimental insomnia drug moved a step closer to U.S. approval on Wednesday after a panel of medical experts said it is effective and safe at lower doses. The advisory panel was convened to help the U.S. Food and Drug Administration decide whether to approve the drug, …

    • Senate committee advances drug compounding bill Jessica Dye - Reuters - Wed, May 22, 2013

      By Jessica Dye NEW YORK (Reuters) - A U.S. Senate committee on Wednesday unanimously approved legislation that would increase federal oversight for companies that compound … More »Senate committee advances drug compounding bill

      By Jessica Dye NEW YORK (Reuters) - A U.S. Senate committee on Wednesday unanimously approved legislation that would increase federal oversight for companies that compound and sell sterile drugs across state lines. The proposed legislation was introduced in response to a meningitis outbreak last fall that killed more than …

    • Vitamin C may not treat gout: study Andrew M. Seaman - Reuters - Wed, May 22, 2013

      By Andrew M. Seaman NEW YORK (Reuters Health) - Daily vitamin C supplements don't lower uric acid as much as drugs used to treat high levels of the acid that's responsible … More »Vitamin C may not treat gout: study

      By Andrew M. Seaman NEW YORK (Reuters Health) - Daily vitamin C supplements don't lower uric acid as much as drugs used to treat high levels of the acid that's responsible for gout, says a new study from New Zealand. "It's not that the vitamin C didn't reduce the uric acid level at all, it's just so small that it wouldn't …

    • ‘Club Drug’ Ketamine Lifts Depression in Hours Maia Szalavitz - Time.com - Wed, May 22, 2013

      The largest study to date confirms that ketamine — a “club drug” that is also legally used as an anesthetic — could be a quick and effective way to relieve depressio … More »‘Club Drug’ Ketamine Lifts Depression in Hours

      The largest study to date confirms that ketamine — a “club drug” that is also legally used as an anesthetic — could be a quick and effective way to relieve depression.

    • Thrifty Merrimack developing new cancer drugs at lower cost Bill Berkrot - Reuters - Wed, May 22, 2013

      By Bill Berkrot NEW YORK (Reuters) - Little known biotechnology company Merrimack Pharmaceuticals Inc has quietly built a large pipeline of experimental cancer treatments … More »Thrifty Merrimack developing new cancer drugs at lower cost

      By Bill Berkrot NEW YORK (Reuters) - Little known biotechnology company Merrimack Pharmaceuticals Inc has quietly built a large pipeline of experimental cancer treatments that it aims to deliver at a fraction of the cost spent by larger rivals. That could translate into lower-cost treatments for large unmet needs, such …

    • A woman walks past the Pfizer Inc. headquarters in New York
      Pfizer to spin off Zoetis stake to shareholders Reuters - Wed, May 22, 2013

      (Reuters) - Pfizer Inc said on Wednesday it will spin off its majority stake in animal health business Zoetis Inc to shareholders by allowing them to swap Pfizer stock … More »Pfizer to spin off Zoetis stake to shareholders

      A woman walks past the Pfizer Inc. headquarters in New York

      (Reuters) - Pfizer Inc said on Wednesday it will spin off its majority stake in animal health business Zoetis Inc to shareholders by allowing them to swap Pfizer stock for Zoetis shares at a 7 percent discount. Pfizer, the largest U.S. drugmaker, sold Zoetis shares in an initial public offering in February that raised $2.2 …

    • EDS NOTE GRAPHIC CONTENT -In this picture provided by the Cancer Center and Institute of Oncology in Gliwice, Poland, a 33-year-old Polish man whose face was torn off by stone-cutting machinery is shown after undergoing a total face transplant. Doctors performed the surgery on May 15 in a 27-hour operation. In a news conference on Wednesday they said it was the first time a life-saving face transplant was carried out soon after a recipient suffered damage. There have been several other transplants in recent years but in those cases doctors had months or years to prepare. The Polish patient suffered his accident on April 23, 2013.(AP Photo/Cancer Center and Institute of Oncology in Gliwice)
      Life-saving face transplant performed in Poland MONIKA SCISLOWSKA - AP - Wed, May 22, 2013

      WARSAW, Poland (AP) — A 33-year-old Polish man received a life-saving total face transplant just three weeks after being disfigured in a workplace accident, in what his … More »Life-saving face transplant performed in Poland

      EDS NOTE GRAPHIC CONTENT -In this picture provided by the Cancer Center and Institute of Oncology in Gliwice, Poland, a 33-year-old Polish man whose face was torn off by stone-cutting machinery is shown after undergoing a total face transplant. Doctors performed the surgery on May 15 in a 27-hour operation. In a news conference on Wednesday they said it was the first time a life-saving face transplant was carried out soon after a recipient suffered damage. There have been several other transplants in recent years but in those cases doctors had months or years to prepare. The Polish patient suffered his accident on April 23, 2013.(AP Photo/Cancer Center and Institute of Oncology in Gliwice)

      WARSAW, Poland (AP) — A 33-year-old Polish man received a life-saving total face transplant just three weeks after being disfigured in a workplace accident, in what his doctors said Wednesday is the fastest timeframe to date for such an operation.

    • Oncolytics cancer drug meets mid-stage trial goal, shares rise Reuters - Wed, May 22, 2013

      (Reuters) - Oncolytics Biotech Inc said preliminary data from a mid-stage trial showed that its cancer drug, Reolysin, met the main goal of reducing the size of tumors … More »Oncolytics cancer drug meets mid-stage trial goal, shares rise

      (Reuters) - Oncolytics Biotech Inc said preliminary data from a mid-stage trial showed that its cancer drug, Reolysin, met the main goal of reducing the size of tumors in patients with metastatic melanoma, a type of skin cancer. Shares of the Calgary-based company rose as much as 11 percent to C$3.14 on the Toronto Stock …

    • Signage is pictured on the company headquarters of GlaxoSmithKline in west London
      U.S. government taps GlaxoSmithKline for new antibiotics Ben Hirschler - Reuters - Wed, May 22, 2013

      By Ben Hirschler LONDON (Reuters) - The U.S. government has signed an antibiotics development deal worth up to $200 million with GlaxoSmithKline to tackle the dual threats … More »U.S. government taps GlaxoSmithKline for new antibiotics

      Signage is pictured on the company headquarters of GlaxoSmithKline in west London

      By Ben Hirschler LONDON (Reuters) - The U.S. government has signed an antibiotics development deal worth up to $200 million with GlaxoSmithKline to tackle the dual threats of drug resistance and bioterrorism. The collaboration, the first of its kind between Washington and a drug company, will allow funding to move around …

    • Immune system cancer drugs tipped to be a $35 billion market Ben Hirschler - Reuters - Wed, May 22, 2013

      By Ben Hirschler LONDON (Reuters) - A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history, with … More »Immune system cancer drugs tipped to be a $35 billion market

      By Ben Hirschler LONDON (Reuters) - A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history, with potential sales of $35 billion a year. That bullish sales forecast by analysts at U.S. bank Citigroup highlights the growing excitement surrounding so-called …

    • A view of the Merck & Co. campus in Linden, New Jersey
      Merck signs $5 billion share buyback agreement with Goldman Sachs Reuters - Wed, May 22, 2013

      (Reuters) - Merck & Co Inc said it has entered into a $5 billion share repurchase agreement with Goldman Sachs Group Inc, as the drug giant looks to prop up shareholder … More »Merck signs $5 billion share buyback agreement with Goldman Sachs

      A view of the Merck & Co. campus in Linden, New Jersey

      (Reuters) - Merck & Co Inc said it has entered into a $5 billion share repurchase agreement with Goldman Sachs Group Inc, as the drug giant looks to prop up shareholder value in face of stiff competition from makers of less-costly generics. Under the accelerated share repurchase agreement (ASR), Merck has agreed to repurchase …

    • Regeneron, Sanofi asthma drug seen as potential game changer Ransdell Pierson - Reuters - Tue, May 21, 2013

      By Ransdell Pierson (Reuters) - A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage … More »Regeneron, Sanofi asthma drug seen as potential game changer

      By Ransdell Pierson (Reuters) - A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease, researchers said on Tuesday. "Overall, these are the most exciting …

    • Vermont passes law allowing doctor-assisted suicide Jason McLure - Reuters - Tue, May 21, 2013

      By Jason McLure (Reuters) - Vermont on Monday became the fourth U.S. state to end legal penalties for doctors who prescribe medication to terminally ill patients seeking … More »Vermont passes law allowing doctor-assisted suicide

      By Jason McLure (Reuters) - Vermont on Monday became the fourth U.S. state to end legal penalties for doctors who prescribe medication to terminally ill patients seeking to end their own lives. The law, which includes a number of safeguards over the next three years as the state adapts, marked the first time a U.S. state …

    • PFIZER WORLD HEADQUARTERS IN NEW YORK.
      Pfizer halts study of lymphoma drug unlikely to help survival Reuters - Mon, May 20, 2013

      (Reuters) - Pfizer Inc, which has been on a hot streak with three recent approvals of cancer drugs, stumbled on Monday, saying it was halting a late-stage trial of a … More »Pfizer halts study of lymphoma drug unlikely to help survival

      PFIZER WORLD HEADQUARTERS IN NEW YORK.

      (Reuters) - Pfizer Inc, which has been on a hot streak with three recent approvals of cancer drugs, stumbled on Monday, saying it was halting a late-stage trial of a drug for aggressive non-Hodgkin lymphoma after independent monitors found it was not likely to improve survival. Pfizer said it would continue to study the …

    • Kelly Martin, President and CEO of Elan, speaks at the Reuters Health Summit in New York
      Royalty raises Elan bid, issues ultimatum to shareholders Padraic Halpin and Jessica Toonkel - Reuters - Mon, May 20, 2013

      By Padraic Halpin and Jessica Toonkel DUBLIN/NEW YORK (Reuters) - Royalty Pharma raised its hostile bid for Elan to $12.50 per share and threatened to withdraw the bid … More »Royalty raises Elan bid, issues ultimatum to shareholders

      Kelly Martin, President and CEO of Elan, speaks at the Reuters Health Summit in New York

      By Padraic Halpin and Jessica Toonkel DUBLIN/NEW YORK (Reuters) - Royalty Pharma raised its hostile bid for Elan to $12.50 per share and threatened to withdraw the bid if Elan shareholders approve a series of defensive transactions announced by the Irish drug firm. Royalty Pharma, which buys royalty streams of patented …

    • Actavis to buy Warner Chilcott in $5 billion stock deal Caroline Humer and Ransdell Pierson - Reuters - Mon, May 20, 2013

      By Caroline Humer and Ransdell Pierson (Reuters) - Generic drugmaker Actavis Inc, itself a recent takeover target, said on Monday it would buy specialty pharmaceutical … More »Actavis to buy Warner Chilcott in $5 billion stock deal

      By Caroline Humer and Ransdell Pierson (Reuters) - Generic drugmaker Actavis Inc, itself a recent takeover target, said on Monday it would buy specialty pharmaceutical company Warner Chilcott Plc for $5 billion in stock to expand its branded drug portfolio, lower taxes and increase profits. The Warner Chilcott acquisition …

     

    Follow Yahoo! News